precisionmedicineonline2 小时
FDA Grants Priority Review to Precigen's Recurrent Respiratory Papillomatosis Gene Therapy
If approved, PRGN-2012 would be the first treatment allowed by the FDA for the rare and chronic disease caused by HPV 6 and HPV 11.